Pharmaceutical companies continue to change capital, spin-off listing into a boom

"Pharmaceutical network industry dynamics" this year, with the rapid pace of capital market reform, especially under the new rules of the GEM overall performance better than the broader market, so that more and more enterprises on the science and technology board, the new rules of the GEM eager to try, listed companies spin off the listing heat gradually increased.
, as on August 9th, Lizhu Group announced that it intended to spin off its controlling subsidiary Lizhu Reagent to list on the A-share market.
According to the announcement, Lizhu Group's main business for pharmaceutical products research and development, production and sales, covering preparation products, API and intermediates and diagnostic reagents and equipment, the company's subsidiary Lizhu reagents for the company focused on diagnostic reagents and equipment manufacturing independent business operating platform.
July 29th, Lep Medical announced that it intended to spin off its controlling subsidiary, Lep Diagnostics, to list on the company.
After the completion of this spin-off, Lepu Medical will further focus on cardiovascular patients, focusing on medical devices, medicine, medical services, new types of medical four major sectors, and further cultivate the cardiovascular medical market, enhance the competitiveness of the industry.
will expand its financing channels, enhance its financial strength, enhance its research and development capabilities and industry competitiveness, and thus enhance the profitability of Lepu Diagnostics through its listing on the Company's board.
May 25, Changchun Gaoxin announced that it intends to spin off its subsidiary Baig Bio into a listing on the SSE.
this spin-off is completed, Changchun High-new equity structure will not change, and still has a controlling stake in Baig Bio.
100 grams of biological main business for the development, production and sale of human biological vaccines, the main products for chickenpox vaccine, human rabies vaccine, nasal influenza vaccine.
According to incomplete statistics, including the above-mentioned enterprises, so far this year, nearly 20 pharmaceutical companies have announced plans to spin off subsidiaries listed, including Changchun High-new, Liaoning Chengda, Hualan Bio, Colum Pharmaceuticals, Tian Shili, Dean Diagnostics, Huabang Health and Yan'an Bikang, Baiyunshan and so on.
from the announced announcement of the proposed spin-off of the subsidiary listed pharmaceutical companies, most of the proposed spin-off subsidiaries in the Branch Ton board, GEM listing.
fact, the industry generally believes that the spin-off listing is conducive to the operation and development of parent companies and subsidiaries.
can first raise the share price of the parent company and subsidiary, and obtain the share price return.
, spin-off and listing is conducive to the implementation of the core strategy, is conducive to their long-term development.
addition, after the listing and circulation of subsidiary shares, management and key employee incentives are more abundant, managers to achieve the role of shareholders, business enthusiasm will be further improved.
, the choice to spin off the listing is more about corporate governance and long-term strategic considerations.
In order to make the overall structure of enterprises more suitable for future business development, pharmaceutical companies are frequently divided or combined strategic turn, especially large pharmaceutical companies, in the past is more and more diversified direction of development, but with the pharmaceutical industry more and more fierce competition, focus has become the industry consensus, and part of the business sector and research and development pipeline divestiture is its inevitable choice.
expected that the future spin-off of subsidiaries or will become more pharmaceutical companies to develop options.
experts believe that the major enterprises mainly split out of diagnostic reagents, vaccines and other bio-innovative drugs are currently sought after by the capital market sector.
its sector investment prospects are bright, but it is worth noting that there is still a need to pay attention to the follow-up research and development investment, product iteration upgrade, market share, talent incentive mechanism and many other issues, prudent operation.